Creador has paid INR2.75 billion ($42 million) for a minority stake in Paras Healthcare, which manages a chain of five hospitals in northern India.
C-Bridge, a Chinese private equity firm that concentrates on late-stage growth capital and buyout opportunities in the healthcare space, has closed its second fund at the hard cap of $400 million.
KKR has agreed to invest approximately $200 million for a 49% stake in India-based Radiant Life Care with a view to helping the specialty hospital operator expand its network of facilities nationwide.
Singapore-government backed Spring Seeds Capital has committed S$100 million ($73 million) to an investment program targeting domestic start-ups developing high-end technology.
Healthcare-focused private equity firm Quadria Capital has acquired stakes in Singapore medical center operator MWH Holdings and Vietnam’s FV Hospital.
France-based venture capital firm Seventure Partners has joined a $13.1 million funding round for Japanese biopharmaceuticals development company Anaeropharma Science.
Zai Lab, a pharmaceutical company that licenses pre-clinical findings in the West for development into drugs in China, has received $30 million in Series C funding led by existing investor OrbiMed.
A consortium of private equity investors has agreed to privatize US-listed Chinese biopharmaceutical player Sinovac Biotech in a deal worth $401.8 million, bringing a contentious bidding process to an end.
The International Finance Corporation (IFC), the investment arm of the World Bank, has invested $60 million in Hong Kong-based medical supply chain solutions provider IDS Medical Systems Group (idsMED).
AGIC Capital, a private equity firm established in 2015 to focus on China-Europe cross-border investments, has secured its first deal in the US with an agreement to acquire pharmaceutical manufacturer Ritedose Corporation.
Emerging Markets Investment Advisers (EMIA) has acquired a significant minority stake in the Cambodia division of iCare Benefits, a Singapore-based company that provides employers with worker benefit programs.
The International Finance Corporation (IFC) is considering an investment of up to $25 million in a Thailand-focused fund launched by Morgan Stanley Private Equity Asia (MSPEA).
BeauCare Clinics, a Chinese plastic surgery clinic chain, has raised RMB200 million ($29 million) in a Series B round of funding led by GP Capital.
WuXi Biologics, a Chinese contract R&D services provider to the global pharmaceutical industry that was taken private by a PE-backed consortium in late 2015, gained 38% on its Hong Kong trading debut following a HK$3.97 billion ($510 million) IPO.
Qiming US Healthcare Fund, a sector specialist vehicle launched by China’s Qiming Venture Partners, has led a $10 million Series A round for Platelet BioGenesis, a Harvard University spin-out that builds human platelets from stem cells.
The Carlyle Group and Pacific Equity Partners (PEP) have finalized an agreement to jointly acquire Australia-based iNova Pharmaceuticals for $930 million in cash.
CDH Investments and Ascendent Capital Partners have teamed up with GL Capital and a Bank of China investment unit in a $605 million bid for US-listed Chinese drug developer SciClone Pharmaceuticals.
Legend Capital has led a $18 million funding round for PhiSkin, a China-based chain of beauty clinics backed by H&Q Asia Pacific.
Australian VC investors Brandon Capital and Uniseed have committed $16 million to Que Oncology, a clinical-stage drug development company established by the University of Queensland (UQ) and US-based Emory University.
Having been supported by fund-of-funds when raising its first China healthcare vehicle, Lyfe Capital has added pension funds, endowments and family offices to its $420 million second fund
Australia’s OneVentures has invested A$10 million ($7.4 million) in Prota Therapeutics, a domestic immunotherapy technology developer aiming to commercialize new peanut allergy treatments for children.
Quadrant Private Equity agrees a $746 million exit from Icon Group, with new owners QIC, Goldman Sachs and Pagoda Investment keen to continue the cancer specialist's expansion in Asia
OrbiMed Asia Partners has led a $19 million Series B round of funding for InventisBio, a pharmaceutical developer based in Shanghai with operations in China and the US.
China-based healthcare specialist Lyfe Capital has raised more than $420 million for its second fund, which comprises parallel US dollar and renminbi-denominated tranches.